Date: 31 Aug 2012
Mechanisms of Drug-Induced Diarrhoea in the Elderly
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In the rapidly increasing elderly population, diarrhoea as a result of drug therapy is an important consideration. The elderly consume a disproportionately large number of drugs for multiple acute and chronic diseases.
Drugs can compromise both immune and nonimmune responses. Aging decreases the quality and proportion of T cells which in turn reduces the production of secretory IgA, the primary immune response of the gut. Acid production in the stomach decreases with increasing age and this compromises its vital ‘self-sterilising’ function, thus increasing the risk of diarrhoea due to viral, bacterial and protozoal pathogens.
Other nonimmune defence mechanisms include the motility of the small intestine and the host—protective commensal bacteria of the colon. Drug induced hypomotility may result in bacterial overgrowth, deconjugation of bile salts and diarrhoea. Less commonly, diarrhoea may occur due to hypermotility because of a cholinergic-like syndrome. In the colon the host-protective commensal bacteria provide a powerful defence against pathogens. Disruption of this commensal population by antibiotic therapy may result in Clostridium difficile supra-infection which causes diarrhoea through toxin production. This is especially important in the elderly patient on chemotherapy for malignancy and those with multiple diseases. The organism responds to vancomycin, metronidazole and bacitracin. Metronidazole is the suggested drug of choice, with vancomycin reserved for relapses.
Drugs also cause diarrhoea by interfering with normal physiological processes. Drugs impair fluid absorption by activating adenylate cyclase within the small intestinal enterocyte which increases the level of cyclic AMP. This causes active secretion of Cl− and HCO3 −, passive efflux of Na+, K+ and water and inhibition of Na+ and Cl− into the enterocyte. Examples of these drugs (secretagogues) are bisacodyl, misoprostol and chenodeoxycholic acid (used to dissolve cholesterol gallstones).
Drugs may also affect a second mechanism that regulates water and electrolyte transport, the Na+,K+ exchange pump. The energy for this pump is provided by the ATPase mediated breakdown of ATP. ATPase may be inhibited by digoxin, auranofin, colchicine and olsalazine.
A number of drugs cause osmotic diarrhoea including antacids containing magnesium trisilicate or hydroxide. Lactulose is being used increasingly in compensated liver disease to increase protein tolerance and prevent hepatic encephalopathy. Sorbitol, an osmotic laxative agent also used in some liquid pharmaceutical preparations, induces diarrhoea by virtue of its osmotic potential.
Another mechanism by which drugs cause diarrhoea is by mucosal damage of the small and large bowel. In the small intestine mucosal damage causes diarrhoea and fat malabsorption, as may occur with neomycin and colchicine. In the colon, for example, gold salts and penicillamine cause colitis of varying severity.
Though the causes of diarrhoea are diverse, a drug-associated aetiology should always be considered and actively sought and addressed to prevent the complications of dehydration, electrolyte imbalance and undernutrition.
Zachariah KC, Vu MT. World Population Projections 1987–1988: short and long term estimates. Baltimore: Johns Hopkins University, 1988
Gambert SR, Guansing AR. Protein-calorie malnutrition in the elderly. J Am Geriatr Soc 1980; 28: 272–5PubMed
Rybolt AH, Bennett RG, Laughon BE, et al. Protein-losing enteropathy associated with Clostridium difficile infection. Lancet 1989; I: 1353–5CrossRef
Clough JD, Minis LH, Strober W. Deficient IgA antibody responses to arsanilic bovine serum albumin (BSA) in neonatally thymectomized rabbits. J Immunol 1971; 106: 1624–9PubMed
Venarucci D, Vallese A, Catalini P, et al. Consideration on diminished immunologic defences in the elderly neoplastic subject. Panminerva Med 1993; 35: 154–8PubMed
Sack Jr GH, Pierce NF, Hennessey KN, et al. Gastric acidity in cholera and non-cholera diarrhoea. Bull World Health Organ 1972; 47: 31–6PubMed
Hunt RH. The protective role of gastric acid. Scand J Gastroenterol 1988; 23: 34–9CrossRef
Axon AT. Potential hazards of hypochlorhydria in the treatment of peptic ulcer [review]. Scand J Gastroenterol 1986; 122 Suppl.: 17–21CrossRef
Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic infections: a perspective. Ann Intern Med 1973; 78: 271–6PubMed
Dymock IW. The gastrointestinal system: the upper gastrointestinal tract. In: Brocklehurst JC, editor. Textbook of geriatric medicine and gerontology. Edinburgh: Churchill Livingstone, 1985: 508–21
Aryeh H, Brady D, Schaal SE, et al. Gastric acidity in older adults. JAMA 1997; 278: 659–62CrossRef
Papadopolous C, Kalantzis N, Rekoumis G, et al. A comparative trial of 400mg cimetidine twice daily and 100mg daily in the short-term treatment of duodenal ulceration. Curr Med Res Opin 1985; 9: 511–5CrossRef
Walker KJ, Gilliland SS, Vance-Bryan K, et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc 1993; 41: 940–6PubMed
Kent TH, Formal SB, LaBrec EH. Acute enteritis due to Salmonella typhimurium in opium-treated guinea pigs. Arch Pathol 1966; 81: 501–8PubMed
Binder HJ. Nutrient induced diarrhoea. In: Field M, editor. Diarrhoeal diseases. New York: Elsevier, 1991; 159–72
Ravdin JI, Guerrant RL. Infectious diarrhoea in the elderly. Geriatrics 1983; 38: 95–7, 99-101PubMed
Cohn CK, Shrivastava R, Mendels J, et al. Double-blind multi-center comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990; 51Suppl. B: 28–33PubMed
Binder HJ, Donowitz M. A new look at laxative action. Gastroenterol 1975; 69: 1001–5
Ewe K. Diarrhoea and constipation. Ballieres Clin Gastroenterol 1988; 2: 353–84CrossRef
Rolfe RD. Interactions among micro-organisms of the indigenous intestinal flora and their influence on the host. Rev Infect Dis 1984; Suppl. 6: S73–9
Fekety R, Kim KH, Batts DH, et al. Studies on the epidemiology of antibiotic-associated Clostridium difficile colitis. Am J Clin Nutr 1980; 33: 2527–32PubMed
Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile—associated diarrhoea and colitis. Lancet 1983; II(8358): 1043–6CrossRef
Clausen MR, Bonnen B, Tvede M, et al. Colonic fermentation to short-chain fatty acids is decreased in antibiotic-associated diarrhea. Gastroenterol. 1991; 101: 1497–504
Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241–9PubMed
Csaky TZ, Hara Y. Inhibition of active intestinal sugar transport by digitalis. Am J Physiol 1965; 209: 467–72PubMed
Hardcastle J, Hardcastle PT, Kelleher DK, et al. Effect of auranofin on absorptive processes in the rat small bowel. J Rheumatol 1986; 13: 541–6PubMed
Fondacaro JD, Henderson LS, Hardcastle PT, et al. Effect of auranofin (SK&F 39162) on water and electrolyte flux in canine small bowel: a possible diarrheogenic mechanism. J Rheumatol 1986; 13: 288–93PubMed
Wallin BA, McCafferty JP, Fox MJ, et al. Incidence and management of diarrhea during longterm auranofin therapy. J Rheumatol 1988; 15: 1755–8PubMed
Champion GD, Cairns DR, Bieri D, et al. Dose response studies and long term evaluation of auranofin in rheumatoid arthritis. J Rheumatol 1988; 15: 28–34PubMed
Campbell DES, Berglindh T. Pharmacology of olsalazine. Scand J Gastroenterol 1988; 23(48): 7–12CrossRef
Forston WC, Tedesco FJ. Drug induced colitis: a review. Am J Gastroenterol 1984; 79: 878–83
Schiller LR. Chronic diarrhoea of obscure origin In: Field M, editor. Diarrhoeal diseases. New York: Elsevier, 1991; 219–38
O’Brien J, Thompson DG, Burnham WR, et al. Beta blocking drugs accelerate the passage of carbohydrate to the colon [abstract]. Gut 1986; 27: 629
Fedorak RN, Rubinoff M. Basic investigations in a patient with diarrhea. In: Field M, editor. Diarrhoeal diseases. New York: Elsevier, 1991; 191–218
Bircher J, Muller J, Guggenheim P, et al. Treatment of chronic portal-systematic encephalopathy with lactulose. Lancet 1966; I: 890–3
Furniss LD. Nonsteroidal anti-inflammatory agents in the treatment of primary dysmenorrhea. Clin Pharm 1982; 1: 327–33PubMed
Puri SK, Ho I, Hsu R, et al. Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer’s disease. J Clin Pharmacol 1990; 30: 948–55PubMed
Henley E. Sorbitol-based elixirs, diarrhea and enterai tube feeding [letter]. Am Fam Physician 1997; 55: 2084–6PubMed
Bytzer P, Stokholm M, Andersen I, et al. Aetiology, medical history, and faecal weight in adult patients referred for diarrhoea: a prospective survey. Scand J Gastroenterol 1989; 25: 572–8CrossRef
Ratnaike RN, O’Halloran MW, Pasco NP, et al. Lactulose lowers arterial ammonia in hepatic failure. Am J Gastroenterol 1972; 58: 626–32PubMed
Martin AE, Montgomery PA. Acarbose: an alpha-glucosidase inhibitor. Am J Health Syst Pharm 1996; 53: 2277–90PubMed
Stemmennann GN, Hayashi T. Colchicine intoxication: a reappraisal of its pathology based on a study of three fatal cases. Hum Pathol 1971; 2: 321–32CrossRef
- Mechanisms of Drug-Induced Diarrhoea in the Elderly
Drugs & Aging
Volume 13, Issue 3 , pp 245-253
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links